Olema Pharmaceuticals/$OLMA
1D1W1MYTD1Y5YMAX
Capital at risk
About Olema Pharmaceuticals
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
- Ticker
- $OLMA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 150
- Headquarters
- San Francisco, United States
- Website
- olema.com
OLMA Metrics
BasicAdvanced
$753M
-
-$2.13
1.99
-
Price and volume
Market cap
$753M
Beta
1.99
52-week high
$36.26
52-week low
$6.65
Average daily volume
1.1M
Financial strength
Current ratio
8.863
Quick ratio
8.757
Long term debt to equity
0.007
Total debt to equity
0.009
Profitability
EBITDA (TTM)
-220.675
Management effectiveness
Return on assets (TTM)
-31.82%
Return on equity (TTM)
-52.74%
Valuation
Price to book
1.75
Price to tangible book (TTM)
1.75
Price to free cash flow (TTM)
-5.015
Free cash flow yield (TTM)
-19.94%
Free cash flow per share (TTM)
-1.717
Growth
Earnings per share change (TTM)
9.98%
3-year earnings per share growth (CAGR)
-4.11%
What the Analysts think about OLMA
Analyst ratings (Buy, Hold, Sell) for Olema Pharmaceuticals stock.
Analyst projections of the future price of Olema Pharmaceuticals stock.
Bulls say / Bears say
Palazestrant has reached two Phase 3 trials, giving Olema a late-stage lead asset rather than a purely speculative pipeline. OPERA-01 is fully enrolled, while OPERA-02 is testing the drug with ribociclib in first-line disease, creating more than one route to a commercial product. (Olema Oncology, Journal of Clinical Oncology)
OP-3136 adds pipeline optionality beyond palazestrant. In Phase 1, it produced tumour shrinkage in 13 of 19 response-evaluable patients, including two confirmed partial responses, and Bayer is supplying darolutamide for a planned prostate-cancer combination study while Olema retains global rights. (Olema Oncology, Olema Oncology)
Olema appears funded through its main near-term catalysts. It ended the second quarter with $461.1 million in cash and marketable securities, and management said this runway extends into the second half of 2028, including Phase 3 execution and preparations for a possible palazestrant launch. (Olema Oncology, StockAnalysis)
The key OPERA-01 catalyst has been pushed back. Olema moved its expected top-line readout from autumn 2026 to the first quarter of 2027, extending the period in which investors face uncertainty over palazestrant’s pivotal efficacy result. (Olema Oncology, Olema Oncology)
OP-3136 remains an early and thinly evidenced programme. Olema had not yet selected a dose or established a maximum tolerated dose, and its initial dataset contained only two confirmed partial responses among 19 response-evaluable patients, so efficacy and longer-term tolerability remain unproven. (StockAnalysis, Olema Oncology)
Olema is still loss-making while spending heavily to run late-stage trials and build commercial infrastructure. Its second-quarter net loss widened to $63.2 million from $43.8 million a year earlier, with R&D expense rising to $57.8 million; a higher-than-planned burn or delay could therefore create future financing and dilution risk despite the stated runway. (StockTitan, Olema Oncology)
Data summarised monthly by Lightyear AI. Last updated on 23 Sept 2026.
OLMA Financial Performance
Revenues and expenses
OLMA Earnings Performance
Company profitability
Upcoming events
No upcoming events
OLMA News
AllArticlesVideos
Funds containing OLMA
AllUSDGBPEUR
Fund name | Fund size | $OLMA weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.05% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.05% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.02% |
SPDR Russell 2000 US Small Cap£R2SC | £4.1B | 0.02% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.